|Articles|May 5, 2017

CDC Updates Zika Testing Guidelines for Pregnant Women

Author(s)Sarah Anwar

The CDC just released updated testing recommendations for asymptomatic pregnant women with possible exposure to the Zika virus.

Only 20% of individuals infected with the Zika virus exhibit symptoms, and those who do usually report mild ones, such as a rash or fever. Unfortunately, however, that is not to say that Zika is completely harmless. Infection during pregnancy can cause neurological complications in the fetus. In addition, time of infection can play a role in the development of such complications; fetuses of women who are infected in the first trimester are at greater risk of Zika-related complications.

Today, May 5, 2017, a Health Alert Notice was issued by the Centers for Disease Control and Prevention (CDC), which updates testing guidelines for asymptomatic pregnant women who were possibly exposed to the Zika virus. Currently, women with possible exposure to the Zika virus are recommended to be tested using Zika virus Immunoglobulin M (IgM) ELISA. This test detects human antibodies or proteins that fight Zika infection. However, “emerging epidemiologic and laboratory data” have revealed that these antibodies may remain in the body for more than 12 weeks after infection in some cases, as with other flavivirus infections, especially those who are asymptomatic. Thus, antibody detection does not necessarily entail a recent infection.

While this information is relevant for all individuals who are exposed to the Zika virus, “it would have the greatest effect on clinical management of pregnant women with a history of living in or traveling to areas with Zika virus transmission,” according to the notice. In addition, the CDC notes infection during pregnancy may also elicit positive results using this test.

The CDC urges asymptomatic pregnant women who were potentially exposed to the Zika virus, either through travel or by residing in areas with active Zika transmission, receive “Zika virus nucleic acid test (NAT) testing at least once per trimester… in addition to IgM testing as previously recommended.”

Administering these two tests together may provide practitioners a more accurate means for “diagnosing recent Zika infection.” Nonetheless, a negative NAT test result does not mean an individual is not infected, since Zika RNA “declines over time.” To better determine if positive IgM results entail recent Zika infection, the CDC recommends “NAT testing of amniocentesis specimens or serial ultrasounds.” The CDC even suggests incorporating IgM into preconception counseling for those women who are not at “ongoing risk” for Zika virus infection, so as to set a baseline for results.

For women who begin to exhibit symptoms, or those whose sexual partners test positive for Zika, NAT testing is recommended. The CDC did not change testing guidelines for pregnant women who exhibit Zika-like symptoms.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.